Navigation Links
International team reveals first prognosticator of survival in aggressive cancer
Date:9/3/2008

(Philadelphia, PA September 4, 2008) The tumor suppressor gene pRb2/p130 may provide the first independent prognostic biomarker in cases of soft tissue sarcoma (STS), according to an international collaboration of researchers, including scientists at the Sbarro Institute for Cancer Research and Molecular Medicine at the College of Science and Technology at Temple University in Philadelphia, PA, the Department of Human Pathology and Oncology, University of Siena and the Center of Oncological Research of Mercogliano (CROM) in Avellino, Italy.

The research appears in the latest issue of Clinical Cancer Research (www.aacrjournals.org).

The findings show that a reduction in the expression of pRb2/p130 can mean a higher risk of recurrence and death from STSs. The gene pRb2/p130, a member of the retinoblastoma family of genes, regulates a portion of the cell cycle.

Clinicians have long sought a prognostic test for the disease, which can be highly aggressive and unpredictable, making it difficult to determine the most beneficial course of chemotherapy and/or radiation treatments following surgery.

A prognostic indicator will help doctors determine which patients have a higher risk of recurrence of the disease and who might benefit from a more aggressive adjuvant therapy.

In the study, researchers examined specimens taken from 41 patients with STS. In a subset of 31 cases of nonmetastatic cancers, they found a direct relationship between pRb2/p130 expression and the clinical outcome of patients.

"We found that pRb2/p130 expression was lost or decreased and significantly correlated with recurrence of disease and poor survival rates in the subset of patients with nonmetastatic tumors," said Valeria Masciullo, M.D., Ph.D., lead author of the study.

"A prognostic test could define the natural history of STSs, while also helping to identify possible targets for new kinds of therapies," said Antonio Giordano, M.D., Ph.D., the Director of the Sbarro Institute, Professor of Molecular Biology at the College of Science and Technology at Temple University in Philadelphia, PA and Full Professor of Pathological Anatomy and Histology of the University of Siena.

The researchers noted that the reliability of pRb2/p130 as a potential marker in the clinical routine assessment and management of patients with STS deserves to be further evaluated in long-term follow-up studies on a larger number of cases.


'/>"/>

Contact: Ilene Raymond Rush
irush@shro.org
215-635-5162
Sbarro Health Research Organization
Source:Eurekalert

Related biology news :

1. [video] Michael DePasquale, CEO of BIO-key International, Inc., Discusses Q2 2008 Revenue Growth on WallSt.nets 3-Minute Press Show
2. NYU Langone Medical Centers tip sheet to the International Conference on Alzheimers Disease 2008
3. International conference to release new findings on smell and taste
4. International team identifies 21 new genetic risk factors for Crohns disease
5. 2008 ASABE Annual International Meeting
6. The 12th International Behavioral Ecology Congress held at Cornell University, Aug. 10-14
7. Biotechnology key to developing sustainable industries says international panel
8. BBVA Foundation international study on attitudes to stem cell research
9. International symposium explores fire suppression economics
10. International workshop to address capacity building for rainforest leaders
11. Great Ape Trust to gather internationally recognized scientists for Decade of the Mind III
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... February 10, 2016 ... to 2016 iris recognition market report, combined ... is more widely accepted for border control. ... fingerprint and iris recognition technology in a ... avoid purchasing two individual biometrics devices. ...
(Date:2/9/2016)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2015.  --> ... was $6.9 million, an increase of 61% compared to $4.3 million ... quarter of 2015 was $2.6 million compared to $0.2 million in ... --> Higher revenue and operating income in the fourth ...
(Date:2/9/2016)... Vigilant Solutions announces today that an agency used ... a lead in a difficult homicide case. The agency then ... the suspect vehicle. Due to the ongoing investigation, the agency ... at the agency,s request. --> ... was found deceased at an intersection here in the City. ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  Allergan plc (NYSE: ... announced that Brent Saunders , Allergan,s CEO and ... a fireside chat session at the RBC Capital Markets ... p.m. ET at The New York Palace Hotel in ... will be webcast live and can be accessed on ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual ... is expecting to fill more than 100 tables for its annual event, which ...
(Date:2/10/2016)... Mateo, CA (PRWEB) , ... February 10, 2016 ... ... of Multiplex Testing (PROMPT), a research registry built on the secure online PatientCrossroads ... September 2014. More than 1,600 participants have joined the PROMPT study, which seeks ...
(Date:2/10/2016)... La Jolla CA (PRWEB) , ... February 10, 2016 , ... ... of new agents for the treatment of Alzheimer’s disease, announced today it has been ... to February 18th at the Breakers in Palm Beach, Florida. The purpose of ...
Breaking Biology Technology: